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H epatocellular carcinoma (HCC) is one of the most common causes of death due to cancer 
worldwide [1].  Surgical resection,  radiofrequency abla-
tion,  and transarterial chemoembolization are com-
monly performed as standard treatment modalities for 
HCC.  Advanced radiotherapy (RT) techniques such as 
three-dimensional conformal radiotherapy (3D-CRT) 
and stereotactic body RT (SBRT),  which provide dose 
escalation to the tumor while minimizing dose exposure 
to organs at risk,  have been introduced as alternatives 
to standard treatment modalities [2-4].
SBRT in 1 to 5 fractions with a fraction size of gen-
erally not less than 6 Gy is performed for small HCCs 
that are < 3 cm in diameter and distant from the gastro-
intestinal tract and kidney,  whereas 3D-CRT is more 
commonly performed for patients who are not candi-
dates for SBRT [5].  These treatment techniques are 
widely regarded to be valuable for HCC treatment,  but 
radiation-induced liver injury remains a problematic 
adverse effect because of pre-existing liver dysfunctions 
that occur secondary to comorbid conditions such as 
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Focal liver reaction (FLR) appears in the hepatobiliary-phase images of gadolinium-ethoxybenzyl-diethylene-
triamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-enhanced MRI) following 
radiotherapy (RT).  We investigated the threshold dose (TD) for FLR development in 13 patients with hepato-
cellular carcinoma (HCC) who underwent three-dimensional conformal radiotherapy (3D-CRT) with 45 Gy in 
15 fractions.  FLR volumes (FLRVs) were calculated based on planning CT images by referring to fused hepato-
biliary-phase images.  We also calculated the TD and the irradiated volumes (IVs) of the liver parenchyma at a 
given dose of every 5 Gy (IVdose) based on a dose-volume histogram (DVH).  The median TD was 35.2 Gy.  The 
median IV20,  IV25,  IV30,  IV35,  IV40,  and IV45 values were 371.1,  274.8,  233.4,  188.6,  145.8,  and 31.0 ml,  
respectively.  The median FLRV was 144.9 ml.  There was a significant difference between the FLRV and IV20,  
IV25,  and IV45 (p< 0.05),  but no significant differences between the FLRV and IV30,  IV35,  or IV40.  These results 
suggest that the threshold dose of the FLR is approx.  35 Gy in HCC patients who undergo 3D-CRT in 15 frac-
tions.  The percentage of the whole liver volume receiving a dose of more than 30-40 Gy (V30-40) is a potential 
candidate optimal DVH parameter for this fractionation schedule.
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hepatitis B/C infection and cirrhosis.  These conditions 
can increase the vulnerability of the surrounding liver 
parenchyma to radiation-induced injury [2 , 6].  Many 
groups have evaluated the relationship between the 
absorbed RT dose and radiation-induced liver injury 
based on a dose-volume histogram (DVH) of RT plan-
ning,  but an optimal parameter has not yet been identi-
fied [6].
Contrast-enhanced magnetic resonance imaging 
(MRI) has an important role in HCC diagnosis [7].  
Among the commercially available liver contrast agents,  
the recently introduced contrast agent gadolinium- 
ethoxybenzyl-diethylenetriamine pentaacetic acid 
(Gd-EOB-DTPA) has theoretical advantages over extra-
cellular agents.  Similar to extracellular contrast agents,  
Gd-EOB-DTPA allows for dynamic perfusion imaging 
to evaluate tumor vascularity.  Additionally,  its absorp-
tion by hepatocytes facilitates liver-specific imaging (i.e.,  
hepatobiliary-phase images) [7 , 8].  Recent reports have 
suggested that Gd-EOB-DTPA-enhanced MRI allows 
for the direct evaluation of the degree of liver damage 
following irradiation [9-11].
Several reports on Gd-EOB-DTPA-enhanced MRI 
following RT suggested that focally decreased enhance-
ment appears in the liver parenchyma of hepatobili-
ary-phase images,  which is often described as a ‘focal 
liver reaction (FLR)’ to radiation [9 , 10 , 12].  The iden-
tification of the threshold dose (TD) that induces FLR 
may facilitate the determination of an optimal DVH 
parameter in RT planning for HCC treatment.  Sanuki 
et al.  [9] recently reviewed patients with HCC who 
underwent SBRT treatment with a total RT dose of 
35-40 Gy in 5 fractions.  They found that for 5 fractions,  
the TD for FLR was 25-30 Gy.  Jung et al.  [13] reviewed 
HCC patients who underwent SBRT treatment with a 
total RT dose of 45 Gy in 3 fractions.  They found that 
for 3 fractions,  the TD for FLR was approx.  20 Gy.  
However,  the TD for other fractionation schedules was 
not fully evaluated.  At our institution,  we usually per-
form moderately hypofractionated 3D-CRT with a total 
dose of 45 Gy administered in 15 fractions to HCC 
patients who are not candidates for SBRT [3].  This 
fractionation schedule has been performed at many 
institutions [14 , 15].  In the present study,  we investi-
gated the TD for FLR in patients with HCC who under-
went 3D-CRT in 15 fractions.
Materials and Methods
Patients. This retrospective study was approved 
by the ethics committee at our institution (No. 864).  
Prior informed consent for treatment and the use of 
data for the study was obtained from all patients.  From 
September 2007 to August 2014,  73 consecutive patients 
underwent 3D-CRT for HCC at our institution.  
Among these patients,  there were 14 who were sub-
jected to Gd-EOB-DTPA-enhanced MRI within 12 
months after the completion of RT.  One patient was 
excluded from this evaluation because we performed 
RT replanning during the treatment period,  leaving a 
final study population of 13 patients.
The patient characteristics are summarized in Table 
1.  All patients were Child-Pugh class A or B with a 
tumor size < 5 cm and had no previous RT.
Radiotherapy. The details of 3D-CRT have been 
reported [3].  The dose distribution was calculated using 
a 3D-radiotherapy planning system (RTPS,  Pinnacle3 
version 8.0-9.2; Philips Medical Systems,  Fitchburg,  
WI,  USA).  For all patients,  a daily fraction of 3 Gy was 
administered at the isocenter to deliver a total dose of 
45 Gy in 15 fractions over 3 weeks.  Three-dimensional 
CRT was performed with a 10-MV linear accelerator 
(Clinac iX; Varian Medical Systems,  Palo Alto,  CA,  
USA) using 3-6 ports.
MRI. We used images of the first MRI study after 
the completion of RT.  The median interval between the 
completion of RT and MRI was 131 days (range 27-279 
days).  MRI was performed using a 3-T MRI system 
(Achieva ; Philips Medical Systems,  Best,  The 
Netherlands).  The baseline MRI examination consisted 
of a breath-hold,  fat-suppressed,  T2-weighted 
sequence; a double-echo T1-weighted gradient-echo 
sequence,  with in-phase and opposed-phase images; a 
diffusion-weighted sequence; and a contrast-enhanced 
dynamic sequence.  Fat-suppressed,  T1-weighted gra-
dient-echo images with a 3D acquisition sequence 
(THRIVE) were obtained precontrast and 5 , 10 , 15 ,  
and 20 min after the intravenous administration of 
0.025 mmol/kg of Gd-EOB-DTPA (Primovist,  Bayer 
Schering Pharma,  Berlin,  Germany).  The images were 
acquired in the transverse plane with a 4-mm section 
thickness and a 4-mm interval.  The repetition time was 
3.1 msec.  The echo time was 1.2 msec.  The flip angle 
was 10°; the number of excitations was 1.  The field of 
view was 40 × 40 cm.  The matrix was 256 × 204,  and the 
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acquisition time was 15.2 sec.
Image analysis. FLR was evaluated on hepatobi-
liary-phase images that were obtained 20 min after 
Gd-EOB-DTPA administration.  Images were trans-
ferred to the RTPS,  and registration between images of 
hepatobiliary-phase and planning CT was performed.  
Two experienced investigators (a radiologist with 9 
years of experience in abdominal MRI and a radiation 
oncologist with 10 years of experience with HCC treat-
ment) confirmed the geometric accuracy of the regis-
tered images and manually delineated the border of the 
focally decreased enhancement area on the planning CT 
images by referring to the hepatobiliary-phase images 
after reaching a consensus.
The FLR volumes (FLRVs) were calculated as the 
delineated volume.  The TD and the irradiated volumes 
(IVs) of the liver parenchyma at a given dose of every 
5 Gy (IVdose) were also calculated based on the DVH of 
the RT planning.
Statistical analysis. We used the Wilcoxon-
signed rank test to compare each IVdose to the FLRV.  All 
statistical analyses were performed using SPSS software 
(ver. 22.0,  Chicago,  IL,  USA).  Differences at p < 0.05 
were considered significant.
Results
The median TD was 35.2 Gy (range 22.8-44.6 Gy).  
The median IV20,  IV25,  IV30,  IV35,  IV40,  and IV45 values 
were 371.1,  274.8,  233.4,  188.6,  145.8,  and 31.0 ml,  
respectively (Table 2).  The median FLRV was 144.9 ml.  
The FLRV was significantly different from IV20,  IV25,  
and IV45,  but there were no significant differences 
between IV30,  IV35,  and IV40 and the FLRV.  An exam-
ple of the dose distribution chart used for RT planning 
and the corresponding hepatobiliary-phase images are 
presented in Fig. 1.
Discussion
A dose-response relationship exists for the HCC 
response to RT [3 , 16],  but there is a fine balance 
between the delivery of a sufficient RT dose to control 
the HCC and avoiding RT-induced liver toxicity.  Tse et 
al.  [17] recommended the prescription of individual-
ized dosing with a fixed fraction number to improve the 
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Table 1　 Patient characteristics
Patient No. Age (yrs) Gender Viral infection
Child-Pugh Largest tumor dia. 
(mm)Class Score
1 68 M HCV A 5 24
2 74 M HCV A 6 40
3 79 F HCV A 6 40
4 78 F HCV A 5 26
5 72 F HCV B 7 43
6 62 M － B 8 49
7 45 M HBV A 6 36
8 54 F HCV B 7 33
9 78 M HCV B 7 36
10 51 F HBV A 6 33
11 77 F HCV A 6 27
12 71 M HCV A 5 27
13 79 M HCV A 5 42
HCV,  hepatitis C virus; HBV,  hepatitis B virus.
Table 2　 Comparison between irradiated volume of the liver 
parenchyma and focal liver reaction volume
Parameter Median (range) p-value＊
IV20 371.1 (158.1-807.9) 0.001
IV25 274.8 (107.6-619.6) 0.013
IV30 233.4 (89.1-538.0) 0.087
IV35 188.6 (70.2-466.1) 0.507
IV40 145.8 (54.4-387.5) 0.279
IV45 31.0 (7.7-130.4) 0.001
FLRV 144.9 (26.7-443.3)
IVdose,  Irradiated volume of the liver parenchyma at a given radiation 
dose; FLRV,  focal liver reaction volume.
＊By Wilcoxon signed-rank test between IVdose and FLRV.
outcomes of patients with HCC.  Finding the dose tol-
erated by the non-tumorous liver tissue based on a fixed 
fraction number may be critical to tailored RT.  The 
results of the present study suggest that the threshold 
dose of FLR is approx.  35 Gy for patients with HCC 
who undergo 3D-CRT in 15 fractions for tumor sizes 
< 5 cm.  Our results,  which were obtained from HCC 
patients treated with moderately hypofractionated RT,  
are consistent with those reported by Sanuki et al.  [9] 
and Jung et al.  [13].  A dose evaluation for recent 
advanced RT techniques was performed based on DVH.  
The previously recommended DVH parameters for 
HCC treatment varied; the percentage of the whole 
liver volume receiving a dose ranged from more than 
5 Gy (V5) to 40 Gy (V40) [6].  Our present findings also 
suggest that V30-V40 is a potential candidate parameter 
for predicting liver damage in patients with HCC who 
undergo 3D-CRT in 15 fractions for a tumor size<5 cm.
Some studies have evaluated RT liver toxicity based 
on an equivalent dose calculation according to the lin-
ear-quadratic model.  Although an α/β ratio of 10 can be 
used to calculate the biologically effective dose (BED) 
delivered to a tumor,  it is difficult to calculate the BED 
delivered to a non-tumorous liver because the α/β ratio 
for non-tumorous liver tissue is unknown.  In fact,  α/β 
ratios ranging from 2 to 10 have been used in previous 
analyses of hepatic toxicity [18-20].  Okamoto et al.  [10] 
evaluated 11 patients with various cancers treated with 
total RT doses of 30-65.4 Gy in 10-35 fractions using 
Gd-EOB-DTPA-enhanced MRI.  Using an α/β ratio of 
10,  they found that the TD was equivalent to the dose 
of 24-29 Gy in 2-Gy fractions.  Their TD results were 
lower than ours,  although we treated patients with the 
larger fraction size of 3 Gy.  Similarly,  their TD results 
were very similar to those reported by Sanuki et al.  [9],  
who evaluated HCC patients who received treatment 
with 7- to 8-Gy fractions.  Their use of an α/β ratio of 
10 might have resulted in an underestimation of the TD.
Our study has some limitations,  including the retro-
spective design and the variability in the interval 
between the RT completion and MRI.  Okamoto et al.  
[10] reported a patient who underwent Gd-EOB-
DTPA-enhanced MRI studies on the 40th and 123rd 
day from the initiation of RT.  The irradiated area in the 
liver of this patient showed a slightly decreased 
enhancement on the 40th day and a clearly decreased 
enhancement on the 123rd day.  The difference in the 
interval between the RT completion and MRI may 
influence the TD and FLRV results.  We also did not 
directly evaluate the potential correlation between the 
TD and the incidence of radiation-induced liver disease 
(RILD); therefore,  we cannot comment on the optimal 
dose constraint of V30-V40 for predicting RILD.  The liver 
tolerance dose might also be influenced by the existence 
or severity of cirrhosis [11 , 21]; however,  we were not 
able to evaluate the potential influence of cirrhosis due 
to the small number of patients evaluated.  Further 
investigations are underway to address this issue.
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0 5 10 15 17Fig. 1　 A dose-distribution chart (A) and hepatobiliary-phase images captured 192 days after the completion of 3D conformal radiother-
apy (B) for Patient 3.  The 35-Gy isodose line (orange line) is almost equal to the focally decreased enhancement area (arrows). The 
threshold dose (TD) of this patient was 35.2 Gy.
In conclusion,  in HCC patients who undergo 
3D-CRT in 15 fractions,  the threshold dose for focal 
liver reaction is approx.  35 Gy.  V30-V40 is a potential 
candidate for an optimal DVH parameter for this frac-
tionation schedule.
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